• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.

作者信息

Berghmans Thierry, Dingemans Anne-Marie, Hendriks Lizza E L, Cadranel Jacques

机构信息

Thoracic Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Dept of Pulmonary Diseases GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, The Netherlands.

出版信息

Eur Respir J. 2020 Feb 6;55(2). doi: 10.1183/13993003.01907-2019. Print 2020 Feb.

DOI:10.1183/13993003.01907-2019
PMID:32029641
Abstract
摘要

相似文献

1
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.非小细胞肺癌的免疫疗法：一种新的治疗算法。
Eur Respir J. 2020 Feb 6;55(2). doi: 10.1183/13993003.01907-2019. Print 2020 Feb.
2
[Immunotherapy for non-small-cell lung cancer].[非小细胞肺癌的免疫疗法]
Rev Prat. 2021 Dec;71(10):1057-1059.
3
Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.非小细胞肺癌免疫治疗的临床方法：现状和未来展望。
Curr Mol Pharmacol. 2016;9(3):183-195. doi: 10.2174/1874467208666150716120108.
4
Immunotherapy in non-small cell lung cancer: advancements and challenges.非小细胞肺癌中的免疫疗法：进展与挑战
Chin Med J (Engl). 2021 Feb 16;134(10):1135-1137. doi: 10.1097/CM9.0000000000001338.
5
Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).晚期非小细胞肺癌（NSCLC）的当前临床免疫治疗靶点。
J Leukoc Biol. 2013 Dec;94(6):1201-6. doi: 10.1189/jlb.0313121. Epub 2013 May 21.
6
Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.评论：新辅助免疫疗法在可切除非小细胞肺癌中的疗效与安全性：一项荟萃分析。
Lung Cancer. 2021 Sep;159:179-180. doi: 10.1016/j.lungcan.2021.04.026. Epub 2021 May 3.
7
Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.免疫疗法单药治疗或化疗联合免疫疗法作为晚期非小细胞肺癌的一线治疗。
Expert Opin Biol Ther. 2019 Mar;19(3):225-232. doi: 10.1080/14712598.2019.1571036. Epub 2019 Jan 25.
8
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.体能状态为2的非小细胞肺癌患者的免疫治疗：证据匮乏情况下的临床决策
J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.
9
Immunologic strategies for the treatment of non-small cell lung cancer.非小细胞肺癌治疗的免疫策略
Surgery. 2002 Jan;131(1 Suppl):S232-5. doi: 10.1067/msy.2002.119794.
10
Perioperative therapy for locoregional nonsmall-cell lung cancer.局部区域非小细胞肺癌的围手术期治疗
J Surg Oncol. 1996 May;62(1):65-74. doi: 10.1002/(SICI)1096-9098(199605)62:1<65::AID-JSO14>3.0.CO;2-S.

引用本文的文献

1
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues.非小细胞肺癌新辅助免疫治疗的文献计量学洞察：趋势、合作及未来方向
Front Immunol. 2025 Feb 10;16:1533651. doi: 10.3389/fimmu.2025.1533651. eCollection 2025.
2
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.一项初步研究评估了 uPath PD-L1（SP263）人工智能（AI）算法在接受 PD-1/PD-L1 检查点抑制剂治疗的 NSCLC 患者中的诊断性能。
Pathologica. 2024 Aug;116(4):222-231. doi: 10.32074/1591-951X-998.
3
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
新型免疫治疗靶点在中、高级肺神经内分泌肿瘤中的表达模式。
Cancer Immunol Immunother. 2024 May 2;73(6):114. doi: 10.1007/s00262-024-03704-7.
4
Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential.抑制 CSF-1R 和 IL-6R 可防止 cDC2 转化为免疫无能的肿瘤诱导 DC3，从而增强 DC 驱动的治疗潜力。
Cell Rep Med. 2024 Feb 20;5(2):101386. doi: 10.1016/j.xcrm.2023.101386. Epub 2024 Jan 18.
5
A Case of Success With Immunotherapy After Changing the Therapeutics Strategy in Non-small Cell Lung Cancer.非小细胞肺癌治疗策略改变后免疫治疗成功的一例病例
Cureus. 2023 Oct 28;15(10):e47874. doi: 10.7759/cureus.47874. eCollection 2023 Oct.
6
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.了解针对非小细胞肺癌的化疗和免疫治疗靶点的可行性：耐药反应及近期联合治疗的最新进展
Explor Target Antitumor Ther. 2023;4(5):850-895. doi: 10.37349/etat.2023.00171. Epub 2023 Oct 10.
7
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy.中性粒细胞与淋巴细胞比值、C反应蛋白和乳酸脱氢酶的基线水平及早期治疗反应在接受免疫治疗的非小细胞肺癌患者中的预后价值
Transl Lung Cancer Res. 2023 Jul 31;12(7):1506-1516. doi: 10.21037/tlcr-23-7. Epub 2023 Jul 14.
8
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.转移性非小细胞肺癌的免疫治疗：治疗进展和生物标志物。
Curr Oncol. 2023 Feb 16;30(2):2366-2387. doi: 10.3390/curroncol30020181.
9
A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer.人类乳腺癌中 T 细胞耗竭相关免疫环境的全面单细胞图谱
Nat Commun. 2023 Jan 6;14(1):98. doi: 10.1038/s41467-022-35238-w.
10
Pseudoprogression in lung cancer: a case report.肺癌中的假性进展：一例报告
Explor Target Antitumor Ther. 2020;1(5):372-380. doi: 10.37349/etat.2020.00022. Epub 2020 Oct 30.